Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Medication Adherence’s Impact on Outcomes in MM

Clin Lymphoma Myeloma Leuk; ePub 2018 Feb 3; Gupta, et al

People with multiple myeloma are prone to experience significant workplace and functional impairment, high out of pocket costs, and frequent office visits, researchers concluded after conducting a cross-sectional study involving 162 individuals. Adherence to therapy can blunt the impact. Participants with multiple myeloma were divided into 2 groups according to their medication adherence scores. They completed 3 surveys, including the Functional Assessment of Cancer Therapy–Multiple Myeloma (FACT-MM): Among the results:

  • FACT-MM scores averaged 98.5.
  • Absenteeism and presenteeism averaged 18% and 52%, respectively.
  • Work productivity and activity impairment averaged 57% and 50%, respectively.
  • Out-of-pocket costs averaged ~$700 in the prior 3 months.
  • Patients spent an average of ~7 hours in monthly appointments with clinicians.
  • Patients with high medication adherence had higher FACT-MM scores.
  • Those with lower medication adherence reported greater activity impairment and were more apt to be overwhelmed/frustrated with appointment rescheduling.
Citation:

Gupta S, Abouzaid S, Liebert R, Parikh K, Ung B, Rosenberg A. Assessing the effect of adherence on patient-reported outcomes and out of pocket costs among patients with multiple myeloma. [Published online ahead of print February 3, 2018]. Clin Lymphoma Myeloma Leuk. doi:10.1016/j.clml.2018.01.006.

This Week's Must Reads

Higher AML, MDS risk linked to autotransplants, Radivoyevitch T et al. Leuk Res. 2018 Jul 19. pii: S0145-2126(18)30160-7

CMS wants to flatten E/M payments, CMS proposed rule, CMS-1693-P

Lay health workers can assist with end-of-life care, Patel MI et al. JAMA Oncology. 2018 Jul 26. doi: 10.1001/jamaoncol.2018.2446.

New guidelines from the UK on chronic lymphocytic leukemia, Schuh AH et al. Br J Haematol. 2018 Jul 15. doi: 10.1111/bjh.15460

JAK1/2 inhibitors tied to increased B-cell lymphoma risk, Porpaczy E et al. Blood. 2018 Jun 14. doi: 10.1182/blood-2017-10-810739.

Must Reads in Myelodysplastic Syndrome

JAK1/2 inhibitors tied to increased B-cell lymphoma risk, Porpaczy E et al. Blood. 2018 Jun 14. doi: 10.1182/blood-2017-10-810739.

Romiplostim safety confirmed in thrombocytopenic patients with low-risk myelodysplastic syndromes, Kantarjian H et al. The Lancet Haematology March 2018, Pages e117-e126 https://doi.org/10.1016/S2352-3026(18)30016-4

Simplifying the URD Selection Process for HCT, Biol Blood Marrow Transplant.; ePub 2018 Feb 14; Shaw, Logan, et al

Genetic Risk Model for MDS Shown to Be Feasible, Am J Hematol; ePub 2018 Feb 24; Gangat, et al

This Predicts Risk of Early Relapse, Death in MM , Biol Blood Marrow Transplant; ePub 2018 Feb 23; Cowan, et al